Winning Points Advisors’s ImmunityBio IBRX Stock Holding History

Winning Points Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.29M	Buy	726,258 +2,685	+0.4%	+$20.3K	3.01%	7
2026 Q1	$5.32M	Buy	723,573 +1,200	+0.2%	+$8.21K	5.32%	5
2025 Q4	$509K	Buy	+722,373	New	+$1.64M	0.54%	27
2024 Q3	$143K	Buy	+89,396	New	+$414K	0.24%	31
2024 Q1	$466K	Hold	92,786	–	–	0.72%	21
2023 Q4	$466K	Buy	92,786 +3,390	+4%	+$10.6K	0.72%	21
2023 Q3	$143K	Sell	89,396 -3,390	-4%	-$6.81K	0.25%	30
2023 Q2	$466K	Sell	92,786 -158,400	-63%	-$448K	0.72%	21
2023 Q1	$461K	Buy	251,186 +8,600	+4%	+$26.7K	0.51%	29
2022 Q4	$1.23M	Sell	242,586 -8,970	-4%	-$49.3K	1.56%	14
2022 Q3	$1.39M	Buy	251,556 +14,600	+6%	+$66.5K	1.7%	14
2022 Q2	$879K	Buy	236,956 +176,830	+294%	+$710K	0.97%	23
2022 Q1	$339K	Buy	+60,126	New	+$369K	0.26%	47
2021 Q4	–	Sell	-43,958	Closed	-$428K	–	74
2021 Q3	$428K	Buy	43,958 +2,483	+6%	+$27.3K	0.31%	45
2021 Q2	$593K	Buy	41,475 +1,475	+4%	+$24.4K	0.44%	40
2021 Q1	$974K	Hold	40,000	–	–	0.73%	32
2020 Q4	$533K	Buy	+40,000	New	+$385K	0.43%	39

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Winning Points Advisors's IBRX Position: Q2 2026 in Review

Winning Points Advisors increased its ImmunityBio (IBRX) stake by 0.37% in Q2 2026, buying an estimated $20.3K and bringing the position to 726,258 shares worth $2.29M. The position accounts for 3.01% of the portfolio, ranked #7.

Winning Points Advisors first reported a position in IBRX in Q4 2020 and has held it in 17 quarters since. The position peaked at $5.32M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Winning Points Advisors held 726,258 shares of ImmunityBio worth $2.29M as of Q2 2026.
Winning Points Advisors bought 2,685 ImmunityBio shares in Q2 2026, an estimated $20.3K.
ImmunityBio made up 3.01% of Winning Points Advisors's portfolio in Q2 2026, its #7 holding.
Winning Points Advisors first reported a position in ImmunityBio in Q4 2020 and has held it in 17 quarters since.
Winning Points Advisors's ImmunityBio position peaked at $5.32M in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Winning Points Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.